Rosuvastatin prevented ischemic stroke in healthy older adults with elevated C-reactive protein

Cruz-Flores, Salvador
June 2010
ACP Journal Club;6/15/2010, Vol. 152 Issue 6, p5
Academic Journal
The article presents information on the study carried out to find if rosuvastatin prevent strokes in older adults with sensitive C-reactive proteins and who do not have hyperlipidemia. The study used randomized placebo-controlled trial. The study showed that rosuvastatin prevented the ischemic stroke. Other details of the study including setting and patients are also highlighted.


Related Articles

  • Is Jupiter Also a God of Primary Prevention? Accad, Michel; Fred, Herbert L. // Texas Heart Institute Journal;2010, Vol. 37 Issue 1, p6 

    The article focuses on the clinical research trial named Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). The trial included 17,802 healthy middle-aged men and women who did not have hyperlipidemia but did have elevated level of...

  • Morbidity predictors in ischemic stroke. Panicker, J.N.; Thomas, M.; Pavithran, K.; Nair, D.; Sarma, P.S. // Neurology India;Mar2003, Vol. 51 Issue 1, p49 

    Reports on a study on morbidity predictors in ischemic stroke. Assessment of focal neurological deficits and functional score; Measurement of C-reactive protein level; Presence of aphasia in some patients.

  • Program of rehabilitative exercise and education to avert vascular events after non-disabling stroke or transient ischemic attack (PREVENT Trial): a multi-centred, randomised controlled trial. MacKay-Lyons, Marilyn; Gubitz, Gordon; Giacomantonio, Nicholas; Wightman, Howard; Marsters, David; Thompson, Kara; Blanchard, Chris; Eskes, Gail; Thornton, Marianne // BMC Neurology;2010, Vol. 10, p122 

    Background: Despite lack of outward signs, most individuals after non-disabling stroke (NDS) and transient ischemic attack (TIA) have significant cardiovascular and cerebrovascular disease and are at high risk of a major stroke, hospitalization for other vascular events, or death. Most have...

  • 2008 - Rosuvastatin prevented major cardiovascular events in persons with elevated C-reactive protein. Campbell-Scherer, Denise L.; Montori, Victor M. // ACP Journal Club;1/1/2009, Vol. 150 Issue 1, p2 

    The article reports that in healthy older adults with elevated C-reactive protein levels who do not have hyperlipidemia, rosuvastatin reduced stroke and myocardial infarction. The randomized placebo-controlled trial titled "Justification for the Use of Statins in Prevention: An Intervention...

  • The Influencing Aspects of Atorvastatin on C-Reactive Protein and Lipid Profile in Patients with Stroke. Anand, A. Vijaya; Chandrasekharan, M.; Kalavathy, S.; Uma, K.; Saravanan, M. P.; Gani, A. Mohamed Saleem; Kumar, K. Vijaya; Senthil, R.; Kumar, P. Sampath // International Journal of Biological Chemistry;2009, Vol. 3 Issue 1, p30 

    The present study was designed to determine the effects of atorvastatin on C-Reactive Protein (CRP) and lipid profile in patients with stroke, since their anti- inflammatory properties have been investigated recently. Ninety five patients with or without stroke were recruited for the study, of...

  • Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. Alvarez-Perez, F. J.; Castelo-Branco, M.; Alvarez-Sabin, J. // Journal of Neurology, Neurosurgery & Psychiatry;Sep2011, Vol. 82 Issue 9, p986 

    Background Classification defined in the Trial of Org10172 in Acute Ischaemic Stroke (TOAST) is widely used in trials and practice. Previous studies on pathophysiology suggest a role for endothelial inflammation in atherothrombotic strokes and intracardiac thrombosis in cardioembolic strokes....

  • A randomized trial on the efficacy of intensive rehabilitation in the acute phase of ischemic stroke. Andrea Di Lauro; Lorenzo Pellegrino; Giuseppe Savastano; Clemente Ferraro; Michele Fusco; Francesco Balzarano; Mirella Marina Franco; Luciano Gaetano Biancardi; Alberto Grasso // Journal of Neurology;Oct2003, Vol. 250 Issue 10, p1206 

    Sixty patients admitted to hospital for hemispherical ischemic stroke causing severe disabilities were enrolled in the study. The patients were divided in two groups: A and B. The patients in group A were given intensive rehabilitative treatment; those in group B were given ordinary...

  • C-Reactive Protein and the risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis. Alla, Venkata M.; Thambidorai, Senthil; Anand, Kishlay; Mooss, Aryan N.; Baltaro, Richard; Mohiuddin, Syed M. // JAFIB: Journal of Atrial Fibrillation;Jan2010, Vol. 1 Issue 10, p569 

    There is increasing evidence linking C-reactive protein (CRP) and atrial fibrillation (AF). Despite the abundance of literature, confusion exists regarding this association because of inconsistent results. MEDLINE and Cochrane Controlled Trials Register databases were carefully searched through...

  • Decreasing homocysteine levels does not decrease vascular risk. Nicklin, David // Patient Care;May2004, Vol. 38 Issue 5, p53 

    Highlights a clinical trial on the association of homocysteine in patients with ischemic stroke. Subjects of the study; Impact of the findings on clinicians.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics